Fragile X Syndrome Therapy Falls Short in Clinical Trials (IMAGE)

American Association for the Advancement of Science (AAAS)

Fragile X Syndrome Therapy Falls Short in Clinical Trials

Caption

Fragile X syndrome (FXS), an inherited disorder caused by mutations in a gene critical to normal brain development, is one of the most common causes of intellectual disability and autistic spectrum disorder. Results from clinical trials show that a promising drug for FXS has no effect on patients' behavior. This material relates to a paper that appeared in the 13 January 2016 issue of Science Translational Medicine, published by AAAS. The paper, by E. Berry-Kravis at Rush University Medical Center in Chicago, IL, and colleagues was titled, "Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials."

Credit

V. Altounian / <i>Science Translational Medicine</i>

Usage Restrictions

Please cite the owner of the material when publishing. This material may be freely used by reporters as part of news coverage, with proper attribution. Non-reporters must contact <i>Science</i> for permission.

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.